Related Experiment Videos
Use of cardiotonic therapy in the management of infants with PPHN
Clinics in Perinatology
|October 1, 1984
Insights
Cardiotonic agents are rationally used in infants with persistent pulmonary hypertension of the newborn (PPHN) when myocardial dysfunction or severe systemic vascular resistance is confirmed. This approach targets specific hemodynamic abnormalities in affected neonates.
Area of Science:
- Neonatal Cardiology
- Pediatric Critical Care
Background:
- Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition in neonates.
- PPHN can be associated with myocardial dysfunction and elevated systemic vascular resistance.
Purpose of the Study:
- To outline the appropriate use of cardiotonic agents in infants diagnosed with PPHN.
- To identify specific criteria for initiating cardiotonic therapy in this population.
Main Methods:
- Review of clinical evidence and guidelines regarding cardiotonic agent use in PPHN.
- Documentation of myocardial function and systemic vascular resistance in affected infants.
Main Results:
- Cardiotonic agents are indicated when myocardial dysfunction is evident.
- Therapy is also warranted in cases of documented extremely abnormal systemic vascular resistance.
Conclusions:
- Rational use of cardiotonic agents is crucial for managing specific PPHN cases.
- Therapy should be guided by comprehensive hemodynamic assessment in neonates.
Abstract:
The author describes the rational use of cardiotonic agents in those infants with PPHN in whom myocardial dysfunction and/or extremely abnormal systemic vascular resistance have been completely documented.